Background: Despite the high contraceptive efficacy and the additional noncontraceptive benefits of the levonorgestrel-releasing intrauterine system (LNG-IUS), concerns persist with respect to its use in nulligravidas. The objective of this study was to evaluate the ease of insertion and clinical performance of the LNG-IUS in nulligravida women up to 1 year after insertion. Methods: Two cohorts were formed after LNG-IUS insertion, one consisting of 159 nulligravidas and the other of 477 parous women. Each nulligravida women was paired with three parous women who had an LNG-IUS inserted on the same day. Insertion was classified as easy or difficult, and when classified as difficult, the use of Hegar dilators and/or misoprostol and insertion failure were additional factors recorded. Results: In almost 80% of cases, no difficulty was encountered during insertion, and dilators and misoprostol were seldom required; however, when necessary, dilator use was almost threefold higher in nulligravida women. Insertion failed in one nulligravida women and in two parous women. Contraception was the most common reason for insertion, although some of the women received the LNG-IUS for both contraceptive and therapeutic purposes, including heavy menstrual bleeding, hematologic diseases, warfarin use, endometriosis-associated pain and following kidney or liver transplantation. The clinical performance of the device showed zero pregnancy rate, expulsion rates of ∼4/100 women-year and 1-year continuation rate of over 90% in both groups. Conclusions: The LNG-IUS is suitable for use by nulligravidas. It is simple to insert, and its clinical performance in nulligravidas is similar to that found in parous women. © 2011 Elsevier Inc. All rights reserved.845e11e16D'Arcangues, C., Worldwide use of intrauterine devices for contraception (2007) Contraception, 75 (6 SUPPL), pp. 2-S7Special Programme of Research, Development and Research Training in Human Reproduction: Task force on the safety and efficacy of fertility regulating methods. The TCu380A, TCu220C, Multiload 250 and Nova T IUDS at 3, 5 and 7 years of use-results from three randomized multicenter trials (1990) Contraception, 42, pp. 141-158. , World Health OrganizationLuukkainen, T., Toivonen, J., Levonorgestrel-releasing intrauterine IUD as a method of contraception with therapeutic properties (1995) Contraception, 52, pp. 269-276Facts on Contraceptive Use Jan 2008, , http://www.guttmacher.org/pubs/fb_contr_use.pdf, The Guttmacher Institute Available at: (Accessed September 2010)Wellings, K., Zhihong, Z., Krentel, A., Barrett, G., Glasier, A., Attitudes towards long-acting reversible methods of contraception in general practice in the UK (2007) Contraception, 76 (3), pp. 208-214. , DOI 10.1016/j.contraception.2007.05.085, PII S0010782407002879Stanwood, N.L., Garrett, J.M., Konrad, T.R., Obstetrician-gynecologists and the intrauterine device: A survey of attitudes and practice (2002) Obstetrics and Gynecology, 99 (2), pp. 275-280. , DOI 10.1016/S0029-7844(01)01726-4, PII S0029784401017264Black, K.I., Sakhaei, T., Garland, S.M., A study investigating obstetricians' and gynaecologists' management of women requesting an intrauterine device (2010) Aust N Z J Obstet Gynaecol, 50, pp. 184-188Grimes, D.A., Forgettable contraception (2009) Contraception, 80, pp. 497-499Bahamondes, L., Faundes, A., Sobreira-Lima, B., Lui-Filho, J.F., Pecci, P., Matera, S., TCu 380A IUD: A reversible permanent contraceptive method in women over 35 years of age (2005) Contraception, 72 (5), pp. 337-341. , DOI 10.1016/j.contraception.2004.12.026, PII S0010782405001587Sivin, I., Utility and drawbacks of continuous use of a copper T IUD for 20 years (2007) Contraception, 75 (6 SUPPL), pp. 70-S75Hidalgo, M.M., Hidalgo-Regina, C., Bahamondes, M.V., Monteiro, I., Petta, C.A., Bahamondes, L., Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system (2009) Contraception, 80, pp. 84-89http://www.paragard.com/health_care_professional/global/pdf/ Prescribing-Info.pdf, Paragard intrauterine copper contraceptive. Prescribing information. Accessed on September 2010http://berlex.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf, Mirena® highlights of prescribing information. Accessed on September 2010Medical Eligibility Criteria for Contraceptive Use, , http://www.who.int/reproductivehealth/publications/family_planning/ 9789241563888/en/, World Health Organization Accessed on September 2010Suhonen, S., Haukkamaa, M., Jakobsson, T., Rauramo, I., Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: A comparative study (2004) Contraception, 69 (5), pp. 407-412. , DOI 10.1016/j.contraception.2003.11.008, PII S0010782403003044Brockmeyer, A., Kishen, M., Webb, A., Experience of IUD/IUS insertions and clinical performance in nulliparous women - A pilot study (2008) Eur J Contracept Reprod Health Care, 13, pp. 248-254Lyus, R., Lohr, P., Prager, S., Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women (2010) Contraception, 81, pp. 367-371. , Board of the Society of Family PlanningTietze, C., Lewit, S., Recommended procedures for the statistical evaluation of intrauterine contraception (1973) Stud Fam Plann, 4, pp. 35-42Zhou, L., Harrison-Woolrych, M., Coulter, D.M., Use of the New Zealand intensive medicines monitoring programme to study the levonorgestrel-releasing intrauterine device (Mirena) (2003) Pharmacoepidemiology and Drug Safety, 12 (5), pp. 371-377. , DOI 10.1002/pds.875Sivin, I., El Mahgoub, S., McCarthy, T., Mishell Jr., D.R., Shoupe, D., Alvarez, F., Brache, V., Stern, J., Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the Copper T 380Ag intrauterine devices: A five-year randomized study (1990) Contraception, 42 (4), pp. 361-378. , DOI 10.1016/0010-7824(90)90046-XChien, L.W., Liu, W.M., Tzeng, C.R., Au, H.K., Effect of previous live birth and prior route of delivery on the outcome of early medical abortion (2009) Obstet Gynecol, 113, pp. 669-674Ofili-Yebovi, D., Ben-Nagi, J., Sawyer, E., Yazbek, J., Lee, C., Gonzalez, J., Jurkovic, D., Deficient lower-segment Cesarean section scars: Prevalence and risk factors (2008) Ultrasound in Obstetrics and Gynecology, 31 (1), pp. 72-77. , DOI 10.1002/uog.5200Ngai, S.W., Chan, Y.M., Tang, O.S., Ho, P.C., The use of misoprostol for pre-operative cervical dilatation prior to vacuum aspiration: A randomized trial (1999) Human Reproduction, 14 (8), pp. 2139-2142. , DOI 10.1093/humrep/14.8.2139Ngai, S.W., Tang, O.S., Ho, P.C., Randomized comparison of vaginal (200 microg every 3 h) and oral (400 microg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy (2000) Hum Reprod, 15, pp. 2205-2208Saav, I., Aronsson, A., Marions, L., Stephansson, O., Gemzell-Danielsson, K., Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: A randomized controlled trial (2007) Human Reproduction, 22 (10), pp. 2647-2652. , DOI 10.1093/humrep/dem244Heikinheimo, O., Inki, P., Kunz, M., Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system (2010) Contraception, 81, pp. 481-486El-Refaey, H., Rajasekar, D., Abdalla, M., Calder, L., Templeton, A., Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol (1995) N Engl J Med, 332, pp. 983-987Dhs, M., Demographic and Health Surveys, , http://www.measuredhs.com/pubs/pub, details.cfm?ID=119&srchTp=. Accessed on September 2010Kaunitz, A.M., Bissonnette, F., Monteiro, I., Lukkari-Lax, E., Muysers, C., Jensen, J.T., Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: A randomized controlled trial (2010) Obstet Gynecol, 116, pp. 625-632. , [Erratum in: Obstet Gynecol 2010;116:999]Fraser, I.S., Non-contraceptive health benefits of intrauterine hormonal systems (2010) Contraception, 82, pp. 396-403Petta, C.A., Ferriani, R.A., Abrão, M.S., A 3-year follow-up of women with endometriosis and pelvic pain users of the levonorgestrel-releasing intrauterine system (2009) Eur J Obstet Gynecol Reprod Biol, 143, pp. 128-129Wong, A.Y.K., Tang, L.C.H., Chin, R.K.H., Levonorgestrel-releasing intrauterine system (Mirena®) and depot medroxyprogesterone acetate (DepoProvera) as long-term maintenance therapy for patients with moderate and severe endometriosis: A randomised controlled trial (2010) Aust N Z J Obstet Gynaecol, 50, pp. 273-279Teitelman, M., Grotegut, C.A., Williams, N.N., Lewis, J.D., The impact of bariatric surgery on menstrual patterns (2006) Obesity Surgery, 16 (11), pp. 1457-1463. , DOI 10.1381/096089206778870148Avgerinos, D.V., Llaguna, O.H., Seigerman, M., Lefkowitz, A.J., Leitman, I.M., Incidence and risk factors for the development of anemia following gastric bypass surgery (2010) World J Gastroenterol, 16, pp. 1867-1870Culwell, K.R., Curtis, K.M., Del Carmen Cravioto, M., Safety of contraceptive method use among women with systemic lupus erythematosus: A systematic review (2009) Obstet Gynecol, 114, pp. 341-353Paulen, M.E., Folger, S.G., Curtis, K.M., Jamieson, D.J., Contraceptive use among solid organ transplant patients: A systematic review (2010) Contraception, 82, pp. 102-112Diaz, J., Bahamondes, L., Monteiro, I., Petta, C., Hildalgo, M.M., Arce, X.E., Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brazil (2000) Contraception, 62, pp. 59-61Backman, T., Huhtala, S., Luoto, R., Tuominen, J., Rauramo, I., Koskenvuo, M., Advance information improves user satisfaction with the levonorgestrel intrauterine system (2002) Obstetrics and Gynecology, 99 (4), pp. 608-613. , DOI 10.1016/S0029-7844(01)01764-1, PII S0029784401017641